Eli Lilly on Monday said its obesity pill Foundayo significantly reduced the severity of obstructive sleep apnea, the most common sleep-related breathing disorder, in patients with obesity, in a late-stage trial. The drugmaker plans to file by the end of the year for U.S. approval of the daily pill for moderate-to-severe obstructive sleep apnea, or OSA, in adults with obesity or who are overweight. The results make the pill — which rolled out in the U.S. in April — one of several GLP-1 treatments to show promise in treating the condition.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.